Renin-angiotensin system blockers (ACE inhibitors or ARBs) and SGLT2 inhibitors have been shown to slow the progression of CKD and reduce CV risk in individuals with diabetes and CKD [13–18], but the significant residual risk remains. Here, REN is linked to diabetes mellitus.